Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

372 ARTÍCULOS , VIENDO DEL 226 AL 240

[Daily functioning in dementia: pharmacological and non-pharmacological interventions demonstrate small effects on heterogeneous scales]

Voigt-Radloff S, Hüll M.

Psychiatr Prax. 2011 Jul;38(5):221-31. doi: 10.1055/s-0030-1266016. Epub 2011 Mar 21.

Insight into amyloid structure using chemical probes

Reinke AA, Gestwicki JE.

Chem Biol Drug Des. 2011 Jun;77(6):399-411. doi: 10.1111/j.1747-0285.2011.01110.x. Epub 2011 Apr 26.

[Neurochemical mechanisms of a novel Alzheimer's disease therapeutics on improvement of cognition and depressive behavior]

Shioda N, Yamamoto Y, Han F, Moriguchi S, Fukunaga K.

Yakugaku Zasshi. 2011 Apr;131(4):505-11. doi: 10.1248/yakushi.131.505.

Amyloid-dependent and amyloid-independent stages of Alzheimer disease

Hyman BT.

Arch Neurol. 2011 Aug;68(8):1062-4. doi: 10.1001/archneurol.2011.70. Epub 2011 Apr 11.

Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study

Barak Y, Plopski I, Tadger S, Paleacu D.

Int Psychogeriatr. 2011 Nov;23(9):1515-9. doi: 10.1017/S1041610211000743. Epub 2011 Apr 15.

A phase II trial of huperzine A in mild to moderate Alzheimer disease

Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, Jin S, Thomas R, Aisen PS; Alzheimer's Disease Cooperative Study.

Neurology. 2011 Apr 19;76(16):1389-94. doi: 10.1212/WNL.0b013e318216eb7b.

Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD

Vigen CL, Mack WJ, Keefe RS, Sano M, Sultzer DL, Stroup TS, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Tariot PN, Zheng L, Schneider LS.

Am J Psychiatry. 2011 Aug;168(8):831-9. doi: 10.1176/appi.ajp.2011.08121844. Epub 2011 May 15.

[Support for patients with Alzheimer's disease and their caregivers by gerontechnology]

Rigaud AS, Pino M, Wu YH, DE Rotrou J, Boulay M, Seux ML, Hugonot-Diener L, DE Sant'anna M, Moulin F, LE Gouverneur G, Cristancho-Lacroix V, Lenoir H.

Geriatr Psychol Neuropsychiatr Vieil. 2011 Mar;9(1):91-100. doi: 10.1684/pnv.2010.0248.

Effect of cholinergic stimulation in early Alzheimer's disease - functional imaging during a recognition memory task

Miettinen PS, Pihlajamäki M, Jauhiainen AM, Tarkka IM, Gröhn H, Niskanen E, Hänninen T, Vanninen R, Soininen H.

Curr Alzheimer Res. 2011 Nov;8(7):753-64. doi: 10.2174/156720511797633241.

Galantamine and behavior in Alzheimer disease: analysis of four trials

Kavanagh S, Gaudig M, Van Baelen B, Adami M, Delgado A, Guzman C, Jedenius E, Schäuble B.

Acta Neurol Scand. 2011 Nov;124(5):302-8. doi: 10.1111/j.1600-0404.2011.01525.x. Epub 2011 May 26.

Bionanotechnologies for treatment and diagnosis of Alzheimer's disease

Moghimi SM.

Nanomedicine. 2011 Oct;7(5):515-8. doi: 10.1016/j.nano.2011.05.001. Epub 2011 May 17.

Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid

Vallabhajosula S.

Semin Nucl Med. 2011 Jul;41(4):283-99. doi: 10.1053/j.semnuclmed.2011.02.005.

The assessment and management of pain in the demented and non-demented elderly patient

Andrade DC, Faria JW, Caramelli P, Alvarenga L, Galhardoni R, Siqueira SR, Yeng LT, Teixeira MJ.

Arq Neuropsiquiatr. 2011;69(2B):387-94. doi: 10.1590/s0004-282x2011000300023.

Cognitive improvement with intrathecal administration of infliximab in a woman with Alzheimer's disease

Shi JQ, Wang BR, Jiang WW, Chen J, Zhu YW, Zhong LL, Zhang YD, Xu J.

J Am Geriatr Soc. 2011 Jun;59(6):1142-4. doi: 10.1111/j.1532-5415.2011.03445.x.

Clinical amyloid imaging in Alzheimer's disease

Herholz K, Ebmeier K.

Lancet Neurol. 2011 Jul;10(7):667-70. doi: 10.1016/S1474-4422(11)70123-5.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias